Top 10 Take-Home Messages FROM THE AHA 24
\n*****************<\/p>\n
Here are 10 highlights from the meeting:<\/p>\n
1.The GLP-1 tirzepatide, the active ingredient in Eli Lilly’s Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity.<\/p>\n
2.In one study, stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death.<\/p>\n
3.Coronary artery calcium scores were found to accurately assess cardiovascular risk for both men and women.<\/p>\n
4.Between 1999 and 2020, obesity-related deaths from heart disease deaths in the U.S. increased by 180%.<\/p>\n
5 One study found ablation treatment may be better than medication for heart attack survivors who develop an abnormal heartbeat.<\/p>\n
6.Giving pharmacists feedback on patients\u2019 heart failure medication rates improved care for veterans with heart failure.<\/p>\n
7.Updates on medications associated with cardiovascular care, including blood thinners and atrial fibrillation, edoxoban and heart valve surgery, spironolactone and heart failure, sacubitril\/valsartan and cardiomyopathy for cancer patients, and bumetanide nasal spray and heart failure.<\/p>\n
8.FDA-approved reconditioned pacemakers worked as well as new devices in a recent study.<\/p>\n
9.Results from a study of a new AI software that reads echocardiagrams was presented and an AI developer won the AHA’s annual Health Tech Competition.<\/p>\n
10.A study found that lifestyle and risk factor modification significantly improved symptoms of atrial fibrillation but did not improve disease burden or progression.<\/p>\n","protected":false},"excerpt":{"rendered":"
Top 10 Take-Home Messages FROM THE AHA 24 ***************** Here are 10 highlights from the meeting: 1.The GLP-1 tirzepatide, the active ingredient in Eli Lilly’s Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity. 2.In one study, stroke survivors who took GLP-1 or SGLT2 medications had a 74% […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5315","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=5315"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5315\/revisions"}],"predecessor-version":[{"id":5316,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5315\/revisions\/5316"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=5315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=5315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=5315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}